To further investigate the efficiency of A80.2HCl action on the MYC, KLHL42 and pRB1 axes identified in our study, we treated bladder cancer, prostate cancer and breast cancer cell lines with increasing doses of A80.2HCl. This evidence concerns the gene PRB1 and breast cancer.